Hariram Motumal Nasta & Renu Hariram Nasta Ophthalmic Plastic Surgery Centre opens at LVPEI

IMT News Desk
IMT News Desk
· 2 min read

LVPEI to further strengthen and scale up the ophthalmic plastic clinical, education and research activities

The comprehensive state-of-the-art ophthalmic plastic surgery centre at LV Prasad Eye Institute’s Kallam Anji Reddy Campus is now named ‘Hariram Motumal Nasta & Renu Hariram Nasta Ophthalmic Plastic Surgery Centre’. Risha Kilaru and Dr Gangadhar Prasad Kilaru, a plastic Surgeon practising in Fremont, California, have extended their support to further strengthen and scale up the ophthalmic plastic services at LV Prasad Eye Institute. In acknowledgement of their support, the centre has been named in honour of Risha Kilaru’s parents.  

The state-of-the-art Ophthalmic Plastic Centre at LVPEI, managed by an experienced team of ophthalmologists and optometrists, is equipped to offer basics to advanced (including navigation-guided and 3D implant surgeries) care to treat a range of eye problems on the structures surrounding the eye, including the eyelids, orbit (bones of the eye socket), lacrimal system (tear duct system), forehead, and midface area. The most common eye conditions managed by this department include droopy eyelids, tearing (watering eye) in children and adults, periocular (surrounding the eyeball) and facial cosmetic concerns, thyroid eye disease, and eye tumours (eye cancer).  

The Ophthalmic Plastic Centre at LVPEI also has a dedicated prosthetic clinic. Injury as well as, certain disorders such as cancers can lead to loss or removal of an eye. While the vision cannot be restored, the appearance can be brought back to near normal, by customised artificial eyes (prosthesis). The team is also actively engaged in research and community outreach initiatives.  

“We extend our sincere gratitude to Risha Kilaru and Dr Gangadhar Prasad Kilaru for their generous support that will help us further strengthen and scale up our ophthalmic plastic clinical, education and research activities,” said Dr Swathi Kaliki, Head, Ophthalmic Plastic Services, LV Prasad Eye Institute. 

 

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk